Small Molecule Compound definition

Small Molecule Compound means a small molecule compound [*] or [*]. For clarity, [*], shall be considered Small Molecule Compounds.
Sample 1Sample 2
Small Molecule Compound means a molecule with a molecular weight less than or equal to [ * ].
Sample 1Sample 2Sample 3
Small Molecule Compound shall have the meaning set forth in the definition of Compound.
Sample 1Sample 2Sample 3

Examples of Small Molecule Compound in a sentence

  • In the event that a party is presented with a Third Party Opportunity for the development and commercialization of a Small Molecule Compound acting through a Selected Target that has not been previously designated as an Inactive Selected Target, a BMS Target or a Lexicon Target, then the party may pursue such Third Party Opportunity, but only in the manner provided in this Section 2.11.

  • For clarity, the licenses granted in Section 7.1 by Exelixis to BMS do not give BMS any right or license (a) to incorporate into any Product (e.g., as a combination product) any compound that is Controlled by Exelixis and that is not a Licensed Compound or (b) to perform any research that is directed to identifying, characterizing, developing or otherwise pursuing any Small Molecule Compound that is not a Licensed Compound.

  • In the event that a Small Molecule Compound or Small Molecule Product shall fail to achieve Regulatory Approval in any country ("Failed Compound"), such milestone amount paid shall be applied to any future Compound or Product put into development by the Joint Project Team ("Replacement Compound").

  • In such case, any Small Molecule Compound selected for Development in accordance with the terms of such definitive agreement that is not a Back-up Product under the terms of such definitive agreement shall be deemed to be a Collaboration Product for purposes of Sections 11.3 and 11.4 if (y) [**] or (z) [**].

  • Subject to the terms and conditions of this Agreement, in the event that Genentech elects not to develop a Small Molecule Compound, pursuant to this Section 3.1.3, or if after electing to develop such a Small Molecule Compound, ceases development, [**].

  • Milestone payments made by Genentech for Small Molecule Compound(s) never reaching a Regulatory Approval are fully creditable back to Genentech at the time of Small Molecule Product or Small Molecule Compound withdrawal from the Collaboration Program.

  • In the event that a party is presented with an opportunity to obtain a license from a Third Party for the development and commercialization of a Small Molecule Compound acting through a Selected Target (a "Third Party Opportunity"), then the party may pursue such Third Party Opportunity, but only in the manner provided in this Section 2.11.

  • In the event that a party is presented with a Third Party Opportunity for the development and commercialization of a Small Molecule Compound acting through a Selected Target that has been previously designated as an Inactive Selected Target, a BMS Target or a Lexicon Target, then the party may pursue such Third Party Opportunity, but only in the manner provided in this Section 2.11.2 and subject to the parties' obligations under Section 2.6.1(b) and Article 8.

  • OncoMed shall acquire no rights to any Small Molecule Compound or other material transferred to it pursuant to this Section 2.6.3 other than as expressly provided in the Celgene Background IP Transfer Agreement, the Master Collaboration Agreement or in this [***]SM Agreement.

  • It is understood between the Parties that, if the Compound is a Small Molecule Compound, Evotec shall conduct the drug discovery activities.


More Definitions of Small Molecule Compound

Small Molecule Compound means any molecule that has a molecular weight [ * ].
Sample 1Sample 2Sample 3
Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, as well as conjugates of such chemical compounds to larger molecules to improve the delivery, bioavailability and/or pharmacokinetic properties of such chemical compound. For clarity, Small Molecule Compound specifically excludes any compound that consists of or incorporates as an active ingredient (i.e., other than to affect the delivery, bioavailability and/or pharmacokinetic properties of the compound) (a) a protein, (b) an antibody or any fragment thereof, (c) an antisense product or (d) an oligonucleotide.
Sample 1
Small Molecule Compound means a composition comprising a chemical compound, whether synthetic or naturally-derived, that is not an Antibody, an Antisense Compound or a Protein.
Sample 1
Small Molecule Compound means any organic, non-peptidic (meaning with maximum four amino acids) Compound with a molecular weight below 800 Daltons, including any salt, amorphous, crystalline, solvate, ester, ether, and/or stereo-isomeric variation thereof, for which Evotec has conducted the drug discovery efforts under the Collaboration Activities as per the JSC’s decision.
Sample 1
Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, [**]. For clarity, Small Molecule Compound specifically excludes any compound that consists of or incorporates as an active ingredient [**] (a) a protein, (b) an antibody or any fragment thereof, (c) an antisense product or (d) an oligonucleotide.
Sample 1

Related to Small Molecule Compound

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Licensed Compound means [***].

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Compounds means any or all of the following chemicals, as the context requires:

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Exempt compound means the same as defined in Rule 2.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Licensed Product means a product or part of a product in the Licensed Field of Use: (A) the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or (B) which is made with, uses or incorporates any Technology.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Combination Product means any combination of the Product with one (1) or more other active ingredients, products or services that is not the Product, where such products are sold either as a fixed dose/unit or as separate doses/units in a single package for a single price.